CRDN submits response to Health Canada’s consultation on ‘Clinical Trial Regulations’
CRDN has submitted a response to Health Canada, highlighting four key recommendations to ensure Canada’s clinical trial regulations are modern, proportionate, and supportive of rare disease research.